Q-omics provides the consensus-scored TEX33 profile across patient tissues and cancer cell-line models. TEX33 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, TEX33 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, TEX33 RNA expression shows 6,346 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUSC, COAD, and STAD as cancer lineages where TEX33 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TEX33 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TEX33 survival associations across molecular data types. TEX33 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TEX33 RNA expression–survival associations across cancer types. High TEX33 expression shows unfavorable associations in THYM, KICH, DLBC, READ and PAAD, but favorable associations in LUSC. The LUSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .012). Together, the overview and detailed table identify LUSC as the clearest survival context for TEX33 RNA expression.
This table summarizes TEX33 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TEX33. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TEX33 shows lower tumor expression in COAD, BRCA and LUSC and higher tumor expression in KIRP. The COAD box plot shows higher TEX33 RNA expression in normal versus tumor tissue (log2 FC = −0.053, t-test p < 0.001).
This table shows molecular features associated with TEX33 in patient tissues and cancer cell lines. In patient samples, TEX33 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TEX33 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
